The present invention is related to formulations containing a combination of dapoxetine or a pharmaceutically acceptable salt thereof with a phosphodiesterase Type 5 inhibitor or a pharmaceutically acceptable salt thereof. The invention is also related to a process for preparing a similar formulation and its use in treatment of erectile dysfunction.